Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730872 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
A Phase 4 study, sponsored by ORA.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01730872: Completed Phase 4 study, sponsored by ORA.
NCT01730872 is a Phase 4 study that has completed, run by ORA. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01730872, a Phase 4 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival redness
Primary Outcome
Ocular inflammation was measured by a masked clinician on a 4-point scale 90 minutes after the conjunctival allergen challenge (CAC) . 0 = best (little to no inflammation), 4 = worst (most inflammation).
Interventions
- DRUG Prednisolone Sodium Phosphate Ophthalmic Solution 1%
- DRUG Tears Naturale II Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT01730872 record still lists
NCT01730872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Prednisolone Sodium Phosphate Ophthalmic Solution 1% is the first listed.
NCT01730872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01730872 about?
NCT01730872 is a clinical study titled "Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model". The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Aller...
What is the current status of trial NCT01730872?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2012-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01730872?
The interventions under investigation include: Prednisolone Sodium Phosphate Ophthalmic Solution 1% (DRUG), Tears Naturale II Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT01730872?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01730872's enrollment target sits among peer trials
16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia